ly-3023414
Small moleculeexperimental
Clinical trial activity
13 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2012 (NCT01655225)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Cholangiocarcinoma · Phase 1
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 2
- Ependymoma · Phase 2
- Glioma · Phase 2
- Healthy Volunteers · Phase 1
- Hepatoblastoma · Phase 2
- Histiocytic Sarcoma · Phase 2
- Histiocytosis, Langerhans-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Medulloblastoma · Phase 2
- Mesothelioma, Malignant · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Neuroblastoma · Phase 2
- Neuroectodermal Tumors · Phase 2
- Osteosarcoma · Phase 2
- Pancreatic Neoplasms · Phase 2
- Rhabdoid Tumor · Phase 2
- Rhabdomyosarcoma · Phase 2
- Sarcoma · Phase 2
- Sarcoma, Ewing · Phase 2
- Wilms Tumor · Phase 2
- Xanthogranuloma, Juvenile · Phase 2
Mechanism of action
- Serine/threonine-protein kinase mTORINHIBITOR
MTOR inhibitor
Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor
- PI3-kinase class IINHIBITOR
PI3-kinase class I inhibitor
Dual MTOR/PIK3 inhibitor, ATP-competitive mTORC1/mTORC2 inhibitor
- Phosphatidylinositol 3-kinase regulatory subunit alpha (PIK3R1) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (PIK3CB) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) ↗
- Phosphatidylinositol 3-kinase regulatory subunit beta (PIK3R2) ↗
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD) ↗
- Phosphoinositide 3-kinase regulatory subunit 5 (PIK3R5) ↗
- Phosphatidylinositol 3-kinase regulatory subunit gamma (PIK3R3) ↗
- PI3-kinase p85-alpha subunit
- PI3-kinase p110-delta subunit
- PI3-kinase p110-alpha subunit
- PI3-kinase p110-gamma subunit
- PI3-kinase p110-beta subunit
- PI3-kinase p85-beta subunit
- PI3-kinase p110-delta/p85-alpha
- PI3-kinase p110-alpha/p85-alpha
- PI3K p110 beta/p85 alpha
- PI3-kinase subunit gamma/Phosphoinositide 3-kinase regulatory subunit 5
- Phosphatidylinositol 3-kinase regulatory subunit beta/Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform/gamma isoform
- PIK3CG/PIK3R1
- Phosphatidylinositol 3-kinase regulatory subunit gamma
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544999 ↗
Also known as
- ly3023414
- ly3023414
- ly-3023414
- ly-3023414
- ly-3023414
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03155620 | Phase 2 | Jul 6, 2017 | National Cancer Institute (NCI) |
| NCT02981342 | Phase 2 | Jan 1, 2017 | Eli Lilly |
| NCT02784795 | Phase 1 | Nov 1, 2016 | Eli Lilly |
| NCT02818335 | Phase 1 | Jul 1, 2016 | Eli Lilly |
| NCT02575703 | Phase 1 | Oct 1, 2015 | Eli Lilly |
| NCT02536586 | Phase 1 | Sep 1, 2015 | Eli Lilly |
| NCT02549989 | Phase 2 | Sep 1, 2015 | Cornell University, Eli Lilly |
| NCT02443337 | Phase 2 | Jul 1, 2015 | Eli Lilly, SCRI Development Innovations |
| NCT02407054 | Phase 2 | Apr 1, 2015 | Eli Lilly, SCRI Development Innovations |
| NCT02124148 | Phase 1 | Jun 18, 2014 | Eli Lilly |
| NCT02057133 | Phase 1 | Mar 10, 2014 | Eli Lilly |
| NCT02079636 | Phase 1 | Mar 1, 2014 | Eli Lilly, Merck |
| NCT01655225 | Phase 1 | Jul 31, 2012 | Eli Lilly |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 12 | 11 | 2 | 2012 |
| SCRI Development Innovations | For profit | 2 | 0 | 1 | 2015 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Merck | For profit | 1 | 0 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2017 |
5 organizations
Page 1 / 1